GRI Bio IncGRI
Price$1.96

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$10.9MTTM through 31 Mar 2026
Free Cash Flow -$12.2MTTM through 31 Mar 2026

Margins

Current

Returns

-18.9%ROE
-17.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Net Debt-$11Mnet cash position
Cash & Equivalents$11M

Quality Metrics

Earnings-Beat Rate25.0%

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Development$0
View details

Focused on advancing clinical development planning for GRI-0621 in the US and Europe, and progressing GRI-0803 toward the clinic.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.